Otsuka Announces FDA Acceptance And Priority Review Of BLA For Sibeprenlimab In Treatment Of Igan
26/05/2025 24:31
May 26 (Reuters) - Otsuka Holdings Co Ltd 4578.T: OTSUKA HOLDINGS CO LTD: OTSUKA ANNOUNCES FDA ACCEPTANCE AND PRIORITY REVIEW OF BLA FOR SIBEPRENLIMAB IN TREATMENT OF IGAN Source text: ID:nTSqy89cc7 Further company coverage: 4578.T (Reporting by Tokyo Newsroom) ((+81345201189;))
Recent news on Otsuka Holdings
See all newsOtsuka, Ionis' experimental ALS drug meets main goal in late-stage study
Brief: Otsuka Pharmaceutical Announces Ulefnersen Early Access Program For Eligible People Living With FUS-ALS
Brief: Otsuka Pharmaceutical Says Phase 3 Fusion Results For Ulefnersen Met Primary Endpoint
Zipalertinib Plus Chemotherapy Demonstrates 6-Month Median Progression-Free Survival Benefit In Rezilient3 Phase 3 Trial In First-Line Egfr Exon 20 Insertion Mutation Non-Small Cell Lung Cancer
Climb Bio rises after early-stage data for kidney disease drug